 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Aethlon Medical Engages Investor Communications Company To Provide Investor Relations Services SAN DIEGO--(BW HealthWire)--Oct. 5, 1999--Aethlon Medical Inc., (formally known as Bishop Equities Inc.) (OTCBB:BSEQ) announced today that it has engaged Investor Communications Co. LLC (ICC) of Rockville, Md. to provide investor relations services. Investor Communications Co. is a national investor relations firm that provides comprehensive, customized investor relations services to small and medium sized emerging public companies. ICC specializes in investor education, analyst communications, media relations, market analysis, and development of corporate communication materials. About Aethlon Medical Aethlon Medical is in the business of acquiring proprietary medical device technologies that can be developed and commercialized on an international basis. The first step in this strategy was initiated through the recent acquisition of Hemex Inc. Hemex has developed a proprietary platform technology known as the Hemopurifier, a device that effectively removes targeted intoxicants from the blood without side effects. The first family of Hemopurifiers to be commercialized has been developed for the purpose of removing harmful metal intoxicants, including, iron, lead, and aluminum. Medical conditions associated with metal intoxication in the body include: cardiovascular disease, permanent organ damage (kidneys, liver), brain damage, impotence in men, early menopause in women, diabetes, and arthritis. Cisplatin, an effective chemotherapeutic agent for treating many forms of cancer, is another intoxicant that can be removed by the Hemopurifier. The side effects associated with the toxicity of Cisplatin are well documented. Future products in the development pipeline include Hemopurifiers designed to remove: (a.) various viruses; (b.) plutonium; and, (c.) drug overdoses. The Hemopurifier is protected by patents in the United States, Europe, and Japan, with additional patents pending. The Hemopurifier is a disposable product which has been designed for use in an established network of dialysis machines located at approximately 6000 hospitals, 2000 freestanding dialysis centers, and 100 regional poison control centers throughout the U.S. Leading participants within the dialysis industry segment include: Baxter International Inc. (NYSE:BAX), Fresenius Medical Care (NYSE:FMS), Renal Care Group Inc. (NASDAQ:RCGI), Minntech Corp. (NASDAQ:MNTX), Renex Corp. (NASDAQ:RENX), Total Renal Care (NYSE:TRL). Aethlon Medical's Web site may be viewed at aethlonmedical.com. CONTACT: Investor Communications Company, 800/457-5580 iccinfo.com To view the 17b disclosure: iccinfo.com | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |